Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). (Source: World Pharma News)
Posted: 2010-07-28 18:00:00
More from this author:
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Multiple Sclerosis Relapses and Severe Disability
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Stress, Fear, Anxiety and MS
From the Web > About.com Multiple Sclerosis: Most Popular Article
From the Web > About.com Multiple Sclerosis: Most Popular Article
Puusepp's sign—Clinical significance of a forgotten pyramidal sign
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Related Articles:
Review of benefits and risks for Tysabri started
From the Web > MedWorm: Multiple Sclerosis
More PML cases prompt Europe's regulators to review Tysabri
From the Web > MedWorm: Multiple Sclerosis
Acorda Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Review Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Panel recommends that FDA Approve fampridine-SR (proposed name Amaya) for symptomatic treatment of MS
From the Web > MedWorm: Multiple Sclerosis
Negative FDA review [of fampridine]
From the Web > MedWorm: Multiple Sclerosis
